Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

Article information

J Korean Med Assoc. 2008;51(12):1151-1157
Publication date (electronic) : 2008 December 31
doi : https://doi.org/10.5124/jkma.2008.51.12.1151
Kyung-Hyo Kim, MD
Department of Pediatrics, Ewha Womans University College of Medicine, Korea. kaykim@ewha.ac.kr

Abstract

Administration of antibodies as a passive immunization is indicated for the replacement of deficiencies, prophylaxis or amelioration of infectious diseases for susceptible individuals and those at high risk for complications of infections. Antibodies can be administered either as human or animal plasma or serum, as pooled human immunoglobulin (IG) for intravenous or intramuscular use, as high-titer human IG from immunized or convalescing donors, or as monoclonal antibodies. Immunoglobulins are widely used for prevention of hepatitis A and measles and specific immunoglobulins are used for prevention of hepatitis B, tetanus, rabies, and varicella in susceptible people. A humanized murine monoclonal antibodies against respiratory syncytial virus have been licensed. This paper reviews the current use and recommendation of antibody products for the prevention and treatment of infectious diseases.

Keywords: Passive Immunization; Immunoglobulins; Infection; Prevention; Treatment

References

1. Pickering LK, Baker CJ, Long SS, McMillan JA, eds. American Academy of Pediatrics. Passive immunization. 2006 Red book: Report of the Committee on infectious diseases 2006. 27th edth ed. Elk Grove Village, IL: American Academy of Pediatrics; 54–66.
2. American Academy of Pediatrics Committee on Infectious Diseases. Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003. 1121442–1446.
3. Keller MA, Stiehm ER. Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin Microbiol Rev 2000. 13602–614.
4. Pickering LK, Baker CJ, Long SS, McMillan JA, eds. American Academy of Pediatrics. Measles. Redbook: 2006 Report of the Committee on Infectious Diseases 2006. 27th edth ed. Elk Grove Village, IL: American Academy of Pediatrics; 441–452.
5. Pickering LK, Baker CJ, Long SS, McMillan JA, eds. American Academy of Pediatrics. Varicella-zoster infections. Redbook: 2006 Report of the Committee on Infectious Diseases 2006. 27th edth ed. Elk Grove Village, IL: American Academy of Pediatrics; 711–725.

Article information Continued

Copyright © 2008 Korean Medical Association

Table 1

Efficacy of antibody in the prevention and treatment of infectious diseases

Table 1

Table 2

Guideline of tetanus prophylaxis in wound management

Table 2

*wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, and frostbite

†Yes, if ≧ 10 years last tetanus-containing dose

‡Yes, if ≧ 5 years last tetanus-containing dose

Table 3

Indications for post-exposure immunoprophylaxis of hepatitis B virus infection

Table 3

Table 4

Indications for post-exposure immunoprophylaxis of varicella zoster virus infection

Table 4

Table 5

Recommended intervals between immunoglobulin administration and MMR immunization

Table 5